BLADDER CANCER: MEDICAL TREATMENT STRATEGIES
https://doi.org/10.17650/1726-9776-2018-14-3-85-91
Abstract
Variety of treatment options for unresectable/metastatic bladder cancer calls for definition of consistency to use medications for different cases. There is expediency to keep vinflunine for bladder cancer as one of effective options.
About the Authors
L. V. Bolotina
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
A. D. Kaprin
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
A. A. Kostin
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
Competing Interests: No conflict of interest.
References
1. Glaser A.P., Fantini D., Shilatifard A. et al. The evolving genomic landscape of urothelial carcinoma. Nat Rev Urol 2017;14(4):215–29. DOI: 10.1038/nrurol.2017.11. PMID: 28169993.
2. Galsky M.D., Hahn N.M., Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer unfit for cisplatin-based chemotherapy. J Clin Oncol 2011;29(17):2432–8. DOI: 10.1200/JCO.2011.34.8433. PMID: 21555688.
3. Balar A.V., Galsky M.D., Rosenberg J.E. et al; IMvigor 210 Study Group. Atezolizumab as first-line treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67–76. DOI: 10.1016/S0140-6736(16)32455-2. PMID: 27939400.
4. Balar A.V., Castellano D., O’Donnell P.H. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(11):1483–92. DOI: 10.1016/S1470-2045(17)30616-2. PMID: 28967485.
5. Gladkov O.A., Matveev V.B., Mitin T. et al. Practical recommendations on the medicinal treatment of malignant tumors. Zlokachestvennye opukholi = Malignant tumors 2017: 411–20. (In Russ.).
6. Bellmunt J., Théodore C., Demkov T. et al. Phase III Trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27): 4454–61. DOI: 10.1200/JCO.2008.20.5534. PMID: 19687335.
7. Médioni J., Di Palma M., Guillot A. et al. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer 2016;16(1):217. DOI: 10.1186/s12885-016-2262-9. PMID: 26975779.
8. Pistamaltzian N., Tzannis K., Pissanidou V. et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs 2016;27(1):48–53. DOI: 10.1097/CAD.0000000000000297. PMID: 26421462.
9. Holmsten K., Dohn L., Jensen N.V. et al. Vinflunine treatment in patients with metastatic urothelial cancer: a Nordic retrospective multicenter analysis. Oncol Lett 2016;12(2):1293–300. DOI: 10.3892/ol.2016.4775. PMID: 27446429.
10. Hussain S.A. ESMO 2016: abstract #800P and poster.
11. Passalacqua R. ASCO 2016: abstract #e16031.
12. Castellano D., Puente J., de Velasco G. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014;14:779. DOI: 10.1186/1471-2407-14-779. PMID: 25342282.
13. Culine S., Theodore C., De Santis M. et al. A phase II study of vinflunine in bladder cancer patients progressing after firstline platinum-containing regimen. Br J Cancer 2006;94(10):1395–401. DOI: 10.1038/sj.bjc.6603118. PMID: 16622447.
14. Vaughn D.J., Srinivas S., Stadler W.M. et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009;115(18):4110–7. DOI: 10.1002/cncr.24460. PMID: 19536904.
15. Retz M., de Geeter P., Goebell P.J. et al. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma – data from a prospective, multicenter experience. BMC Cancer 2015;15:455. DOI: 10.1186/s12885-015-1434-3. PMID: 26040470.
16. Grivas P. ASCO Annual Meeting, 2018.
17. Petrylak D.P., de Wit R., Chi K.N. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet 2017;390(10109): 2266–77. DOI: 10.1016/S0140-6736(17)32365-6. PMID: 28916371.
18. Powles T., Duran I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor 211): a multicenter, open-label, phase 3 randomized controlled trial. Lancet 2017.
19. Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum based chemotherapy: a single arm, multicenter, phase II trial. Lancet 2016;387(10031):1909–20. DOI: 10.1016/S0140-6736(16)00561-4. PMID: 26952546.
20. Bellmunt J., de Wit R., Vaughn D.J. et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683. PMID: 28212060.
21. Sharma P., Callahan M.K., Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (Check-Mate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17(11):1590–8. DOI: 10.1016/S1470-2045(16)30496-X. PMID: 27733243.
22. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Check-Mate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. DOI: 10.1016/S1470-2045(17)30065-7. PMID: 28131785.
23. Powles T., O’Donnell P.H., Massard C. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3(9):e172411. DOI: 10.1001/jama-oncol.2017.2411. PMID: 28817753.
24. Apolo A.B., Infante J.R., Balmanoukian A. et al. Avelumab, an antiprogrammed death-ligand 1 an body, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 2017;35:2117–24.
25. www.thelancet.com/oncology. Vol. 19. July 2018, e341.
26. Rosenberg J.E. EV-101: updated results from phase I study of enfortumab vedotin in patients with metastatic urothelial cancer ASCO 2018. Abstract 4504. Clinical-Trials. gov. NCT02091999.
Review
For citations:
Bolotina L.V., Kaprin A.D., Kostin A.A. BLADDER CANCER: MEDICAL TREATMENT STRATEGIES. Cancer Urology. 2018;14(3):85-91. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-3-85-91
Views:
833
Email this article 